Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (TSE:MSCL)
TSX:MSCL
MSCL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.38 - C$1.32
Previous CloseN/A
Volume29.01K
Average Volume (3M)152.72K
Market Cap
$133.43M
Enterprise ValueC$28.57M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 27, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding153,370,390
10 Day Avg. Volume38,222
30 Day Avg. Volume152,721
Standard Deviation0.26
R-Squared0.01
Alpha0.00794
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.23Price Target Upside59.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience to Showcase at Oppenheimer Healthcare Conference
PremiumCompany Announcements
Satellos Bioscience Secures $40 Million Funding Boost
PremiumCompany Announcements
Satellos Bioscience Announces Public Offering of Shares
PremiumCompany Announcements
Satellos Advances in Duchenne Muscular Dystrophy Trial
PremiumCompany Announcements
Satellos Bioscience Joins Rare Disease Summit
PremiumCompany Announcements
Satellos Bioscience to Host Duchenne Investor WebinarPremiumCompany Announcements
Satellos Bioscience Strengthens Board with New Appointment---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNo drug-related adverse events have been reported to date in the Phase 1 study of SAT-3247.
Market PotentialSAT-3247 shows therapeutic potential in dogs with golden retriever muscular dystrophy, a recognized model for Duchenne muscular dystrophy.
Regulatory MilestonesSAT-3247 received Rare Pediatric Disease Designation by the FDA for the treatment of DMD.
Bears Say
Enrollment ChallengesManagement expects to complete enrollment of the SAD and MAD cohorts by YE2024 and 1Q25, respectively, indicating progress in clinical trials.
Financial OutlookSatellos expects to report SAD and MAD data in 1Q25, which could be a catalyst for the stock.
RisksRisks identified include clinical, regulatory, commercial, competition, and dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$0.38 and its highest was C$1.32 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is $133.43M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Mar 27, 2025 which is in 48 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Nov 13, 2024. The company reported -C$0.08 earnings per share for the quarter, missing the consensus estimate of -C$0.05 by -C$0.03.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.04.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 153,370,390 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.08 in its last earnings report, missing expectations of -C$0.05. Following the earnings report the stock price went up 1.19%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
---
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$1.23 (59.77% Upside)
C$1.23 (59.77% Upside)
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.38%
12-Months-Change
Fundamentals
Return on Equity
-84.66%
Trailing 12-Months
Asset Growth
-50.23%
Trailing 12-Months
Company Description
Satellos Bioscience
iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.
---
MSCL Stock 12 Month Forecast
Average Price Target
C$1.23
▲(59.77% Upside)
Technical Analysis
Best Analysts Covering MSCL
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+41.58%
reiterated a buy rating 3 months ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +41.58% per trade.
---